Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance

Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.

    Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down

    Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.

      Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales

      Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.

        Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2

        Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.

          Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise

          Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.

            Mallinckrodt (MNK) Beats on Q2 Earnings and Sales, Ups View

            Mallinckrodt (MNK) surges following earnings and sales beat in the second quarter. Increase in annual guidance is impressive as well.

              Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2

              The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.

                Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat

                Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.

                  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

                  The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

                    Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected

                    Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.

                      Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

                      Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.

                        Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y

                        The Medicines Company (MDCO) beats earnings estimates while missing the same for revenues in the second quarter.

                          Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track

                          Ophthotech reports narrower-than-expected loss in the second quarter.

                            Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down

                            Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.

                              Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit

                              Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

                                Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates

                                Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.

                                  Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK

                                  The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.

                                    Is a Beat in Store for Vertex (VRTX) This Earnings Season?

                                    Vertex Pharma (VRTX) is expected to beat estimates when it reports second-quarter earnings on Jul 25.

                                      Company News For Jul 2, 2018

                                      Companies in the news are: STZ,KBH,VRTX,FCAU

                                        Vertex's Shares Rally as a Rival's CF Candidate Disappoints

                                        Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

                                          Kinjel Shah headshot

                                          4 Drug and Biotech Stocks Awaiting FDA Decisions in July

                                          In the first six months of the year, the FDA grants approval to 17 new treatments.

                                            Sweta Killa headshot

                                            Sarepta Pharma Pushes Two Biotech ETFs to New Highs

                                            The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

                                              Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

                                              The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

                                                Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                                                Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                                                  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

                                                  FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.